Research Article
Neopterin and Beta-2 Microglobulin Relations to Immunity and Inflammatory Status in Nonischemic Dilated Cardiomyopathy Patients
Table 1
Clinical data of all dilated cardiomyopathy patients (DCM) and comparison between groups A and B.
| | | DCM
= 169 | Group A
= 46 | Group B
= 123 | A versus B |
| | Sex M/F | 133/36 | 40/6 | 93/30 | ns | | Age, y (±SD) | 43.2 (±10.4) | 44.01 (±9.9) | 42.9 (±10.5) | ns | | Hypertension (%) | 49 (28.99) | 13 (28.26) | 36 (29.26) | ns | | Diabetes mellitus (%) | 10 (5.91) | 3 (6.52) | 7 (5.69) | ns | | Prior infection (%) | 33 (19.52) | 10 (21.73) | 24 (18.69) | ns | NYHA functional class
I/II/III/IV (%) | 13/90/58/8
(8/53/34/5) | 2/16/26/2
(4/35/57/4) | 11/74/32/6
(9/60/26/5) | <0.05 | | ECG (%) | | | | | | Normal | 16 (9.4) | 5 (10.8) | 11 (8.9) | ns | | LBBB | 32 (18.9) | 8 (17.3) | 24 (19.51) | ns | | RBBB | 7 (4.14) | 2 (3.34) | 5 (4.06) | ns | | Atrial fibrillation | 37 (21.89) | 11 (23.91) | 26 (21.13) | ns | | LV-overload | 38 (22.48) | 11 (23.91) | 27 (21.95) | ns | | UKG ± SD | | | | | | EF (%) | 29.67 ± 11.37 | 28.67 ± 11.27 | 30.04 ± 11.41 | ns | | LV EDV (mL) | 189.81 ± 79.07 | 196.30 ± 76.77 | 187.39 ± 80.4 | ns | | LVESV (mL) | 139.53 ± 68.72 | 144.43 ± 63.17 | 137.71 ± 70.8 | ns | | Left atrium (cm2) | 21.96 ± 5.45 | 22.69 ± 5.30 | 21.69 ± 5.51 | ns | | Right ventricle (cm) | 3.32 ± 0.59 | 3.39 ± 0.6 | 3.30 ± 0.59 | ns | | Biopsy | | | | | | CD3 (/HPF) | 1.04 ± 0.75 | 1.99 ± 0.78 | 0.68 ± 0.70 | <0.01 | | Mac (/HPF) | 2.25 ± 2.01 | 3.31 ± 2.99 | 1.86 ± 1.65 | <0.01 | | Dallas active (%) | 20 (11.8%) | 12 (26.1%) | 8 (6.5%) | <0.01 | | Dallas borderline | 70 (41.4%) | 22 (47.8%) | 48 (39.0%) | ns | | Dallas no MCI | 79 (46.8%) | 12 (26.1%) | 67 (54.5%) | <0.01 |
|
|
